Arbutus Biopharma Corp at JMP Securities Life Sciences Virtual Conference Transcript
All right, great. Well, thanks, everyone, for joining us again for the JMP Securities' life sciences conference. My name is Roy Buchanan on the biotech team on the research side. Our next company is Arbutus Biopharma, which we rate a market outperform. And we've got most of the senior management team of Arbutus here, including Bill Collier, President and CEO; Dave Hastings, Chief Financial Officer; Mike Sofia, Chief Scientific Officer; and Gaston Picchio, Chief Development Officer. So thanks for joining, everybody.
So just -- Arbutus is almost a pure-play company focused on chronic hepatitis B, HBV. They also have a recent coronavirus program that made sense, obviously, given the pandemic and the team's expertise. But, clearly, chronic HBV is an important global health problem. Bill, if you want to give a quick intro to the Company, or we can just dive into the questions right away?
I think just dive into the questions. Morning.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
